Core Insights - Neuralink successfully raised $600 million in a funding round, achieving a valuation of $9 billion, setting a new record in the brain-computer interface sector [1] - Since its establishment in 2016, Neuralink has focused on developing invasive brain-computer interface technology to enable direct interaction between the human brain and external devices [3] - The company received FDA approval to initiate human clinical trials in 2023, with the first brain-computer interface chip implantation surgery scheduled for January 2024 [3] - The first trial participant, a patient with ALS, has shown positive recovery, demonstrating the ability to control a computer cursor and browse the web using thoughts, validating the device's feasibility [3] - Neuralink's valuation has significantly increased over time, from $3.5 billion in November 2023 to $5 billion in August 2023 after a $280 million Series D funding round, and ultimately reaching $9 billion in the latest funding round [3] - The company's long-term goals include not only repairing neural system damage but also exploring advanced applications such as cognitive enhancement [4] - Neuralink plans to complete 20-30 implantation surgeries by 2025 and initiate the Blindsight project to explore restoring vision through brain-computer interfaces [4] - The first product, Telepathy, utilizes the N1 chip implanted in the brain to enable thought-controlled operation of external devices, featuring high-density flexible electrodes that support 1,024-channel signal transmission to capture neuronal activity [4]
马斯克旗下Neuralink完成6亿美元融资 估值飙升至90亿美元
Huan Qiu Wang·2025-05-28 01:51